Q2 2026 13F · SEC CIK 1839435
Octagon Capital Advisors LP
Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $1.1B
- Reported positions
- 26
- Top holdings a year, 3 yrs
- +43.6%
- Assets under management
- $1.2B
Octagon Capital Advisors LP is a hedge fund that reported 26 positions worth $1.1B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Dianthus Therapeutics Inc (DNTH, 16.5%), Definium Therapeutics Inc (12.7%), Abivax SA (ABVX, 12.1%). A portfolio copying its top holdings returned 43.6% a year over the last 3 years, against 20.4% for the S&P 500.
Octagon Capital Advisors LP holdings all 26 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
What Octagon Capital Advisors LP bought and sold in Q2 2026, against Q1 2026.
New positions
- SMMT Summit Therapeutics Inc1.7% of 13F
- ANL Adlai Nortye Ltd1.0% of 13F
- FTH Faeth Therapeutics Inc0.8% of 13F
- GYRE Gyre Therapeutics Inc0.6% of 13F
Added to
- PHVS Pharvaris N V+176.8% shares
- ABVX Abivax SA+46.7% shares
- Definium Therapeutics Inc+20.9% shares
- TSHA Taysha Gene Therapies Inc+9.4% shares
Reduced
- TRVI Trevi Therapeutics Inc-78.8% shares
- CNTX Context Therapeutics Inc-41.9% shares
- DTIL Precision Biosciences Inc-39.6% shares
- OCUL Ocular Therapeutix Inc-34.5% shares
- KYMR Kymera Therapeutics Inc-27.1% shares
- DNTH Dianthus Therapeutics Inc-5.4% shares
Sold out
- CNTA Centessa Pharmaceuticals PLCwas 3.3%
- KALV Kalvista Pharmaceuticals Incwas 3.2%
- TERN Terns Pharmaceuticals Incwas 3.1%
- BBOT Bridgebio Oncology Therapeutwas 0.7%
- LXEO Lexeo Therapeutics Incwas 0.7%
- CATX Perspective Therapeutics Incwas 0.4%
- EVMN Evommune Incwas 0.4%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +94.5% /yr
- S&P 500 +20.1%
- 3 years
- +43.6% /yr
- S&P 500 +20.4%
- 5 years
- +16.0% /yr
- S&P 500 +11.6%
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $1.1B | 26 |
| Q1 2026 | $903.6M | 29 |
| Q4 2025 | $798.8M | 26 |
| Q3 2025 | $640.6M | 26 |
| Q2 2025 | $455.6M | 30 |
| Q1 2025 | $508.2M | 34 |
| Q4 2024 | $587.9M | 31 |
| Q3 2024 | $624.7M | 41 |
| Q2 2024 | $606.1M | 44 |
| Q1 2024 | $822.6M | 56 |
| Q4 2023 | $625.0M | 33 |
| Q3 2023 | $568.0M | 35 |
Questions about Octagon Capital Advisors LP's portfolio
What stocks does Octagon Capital Advisors LP own?
Octagon Capital Advisors LP's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 26 positions worth $1.1B. The largest are Dianthus Therapeutics Inc (DNTH) at 16.5%, Definium Therapeutics Inc at 12.7%, Abivax SA (ABVX) at 12.1%, Cogent Biosciences Inc (COGT) at 8.3% and Alumis Ord (ALMS) at 7.3%.
What did Octagon Capital Advisors LP buy last quarter?
In Q2 2026, Octagon Capital Advisors LP added a new position in Summit Therapeutics Inc (SMMT), a new position in Adlai Nortye Ltd (ANL), a new position in Faeth Therapeutics Inc (FTH), a new position in Gyre Therapeutics Inc (GYRE), Pharvaris N V (PHVS) (+176.8% shares), Abivax SA (ABVX) (+46.7% shares) and Definium Therapeutics Inc (+20.9% shares), compared with its Q1 2026 filing.
What did Octagon Capital Advisors LP sell last quarter?
In Q2 2026, Octagon Capital Advisors LP sold all of Centessa Pharmaceuticals PLC (CNTA), sold all of Kalvista Pharmaceuticals Inc (KALV), sold all of Terns Pharmaceuticals Inc (TERN), sold all of Bridgebio Oncology Therapeut (BBOT), sold all of Lexeo Therapeutics Inc (LXEO), Trevi Therapeutics Inc (TRVI) (-78.8% shares), Context Therapeutics Inc (CNTX) (-41.9% shares) and Precision Biosciences Inc (DTIL) (-39.6% shares), compared with its Q1 2026 filing.
How has Octagon Capital Advisors LP's portfolio performed?
A portfolio copying Octagon Capital Advisors LP's 20 largest 13F holdings each quarter, from the day each filing was public, returned +43.6% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +94.5% against +20.1%. Over 5 years: +16.0% a year against +11.6%.
When is Octagon Capital Advisors LP's next 13F filing due?
13F filings are due 45 days after each quarter ends. Octagon Capital Advisors LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Octagon Capital Advisors LP manage?
Octagon Capital Advisors LP reported $1.2B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $1.1B.